| Unadjusted | Adjusted (n=186) | ||
---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Recurrence | Â | Â | Â | Â |
Lymph node positivitya | 2.86 (1.65-4.96) | <0.001 | 2.20 (1.18-4.10) | 0.013 |
ER/PR negativityb | 1.90 (1.08-3.37) | 0.027 | 1.53 (0.85-2.77) | 0.156 |
Age | 1.01 (0.98-1.04) | 0.479 | - | - |
BMIc | 1.00 (0.93-1.08) | 1.000 | - | - |
Combined therapyd | 2.64 (1.46-4.78) | 0.001 | 2.03 (1.01-4.08) | 0.046 |
APOA1 rs670 A/Ae | 4.02 (2.22-9.96) | 0.001 | 3.02 (1.25-7.29) | 0.014 |
Mortality | Â | Â | Â | Â |
Lymph node positivitya | 6.01 (2.62-13.80) | <0.001 | 2.09 (1.01-4.29) | 0.046 |
ER/PR negativityb | 2.30 (1.13-4.70) | 0.022 | 4.54 (1.88-10.94) | 0.001 |
Age | 1.03 (0.99-1.06) | 0.127 | - | - |
BMIc | 1.00 (0.91-1.10) | 0.942 | - | - |
Combined therapyd | 3.45 (1.50-7.98) | 0.004 | 2.11 (0.84-5.31) | 0.114 |
APOA1 rs670 A/Ae | 6.30 (2.47-16.08) | <0.001 | 4.47 (1.56-12.79) | 0.005 |